© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90621 refers to the meningococcal recombinant lipoprotein vaccine, specifically targeting serogroup B (MenB-FHbp). This vaccine is designed for intramuscular administration and is indicated for individuals aged 10 years and older. The primary purpose of this vaccine is to prevent infections caused by the bacterium Neisseria meningitidis serogroup B, which is known to be a significant cause of meningitis and sepsis. The N. meningitidis serogroup B bacterium is prevalent globally and is transmitted through respiratory droplets and oral secretions, such as those exchanged during coughing, kissing, or sharing food and utensils. Infection with this bacterium can lead to severe health complications, including meningitis, which is an inflammation of the protective membranes covering the brain and spinal cord, and sepsis, a life-threatening response to infection that can result in organ failure. The consequences of such infections can be dire, potentially leading to fatalities within hours or days, or causing long-term disabilities such as hearing loss, cognitive impairments, and limb amputations. The CPT® Code 90621 is part of a broader classification of vaccines, which includes other codes such as 90620, which reports the meningococcal recombinant protein and outer membrane vesicle vaccine (MenB-4C) administered on a two-dose schedule. In contrast, the MenB-FHbp vaccine (CPT® Code 90621) can be administered in either a two or three-dose schedule, typically at intervals of 0, 2, and 6 months. It is important to note that these codes specifically report the vaccine supply, while the administration of the vaccine is billed separately.
© Copyright 2025 Coding Ahead. All rights reserved.
The meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), is indicated for the prevention of infections caused by Neisseria meningitidis serogroup B in individuals aged 10 years and older. This vaccine is particularly important for those at increased risk of meningococcal disease, which can lead to severe health complications such as meningitis and sepsis.
The administration of the meningococcal recombinant lipoprotein vaccine (CPT® Code 90621) follows a structured dosing schedule. The vaccine can be given in either a two or three-dose regimen. The two-dose schedule typically involves administering the first dose followed by a second dose at least one month later. Alternatively, the three-dose schedule consists of administering the vaccine at three specific intervals: the first dose is given at the initial visit, the second dose is administered two months later, and the third dose is given six months after the first dose. This structured approach ensures optimal immune response and protection against the serogroup B strain of N. meningitidis.
After the administration of the meningococcal recombinant lipoprotein vaccine, patients are typically monitored for a short period to observe for any immediate adverse reactions. Common post-vaccination care includes advising patients about potential side effects, which may include soreness at the injection site, mild fever, or fatigue. It is important for healthcare providers to inform patients about the importance of completing the full vaccination series to ensure maximum protection against N. meningitidis serogroup B. Additionally, patients should be encouraged to report any unusual or severe reactions following vaccination to their healthcare provider.
| Short Descr | MENB-FHBP VACC 2/3 DOSE IM | Medium Descr | MENB-FHBP RECOMBNT LIPOPROTEIN VACC 2/3 DOSE IM | Long Descr | Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use | Status Code | Excluded from Physician Fee Schedule by Regulation | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Items and Services Not Billable to the MAC | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | P6D - Minor procedures - other (non-Medicare fee schedule) | MUE | 1 |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | CR | Catastrophe/disaster related | GA | Waiver of liability statement issued as required by payer policy, individual case | GX | Notice of liability issued, voluntary under payer policy | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | GZ | Item or service expected to be denied as not reasonable and necessary | JZ | Zero drug amount discarded/not administered to any patient | SK | Member of high risk population (use only with codes for immunization) | SL | State supplied vaccine | UC | Medicaid level of care 12, as defined by each state |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2018-01-01 | Changed | First appearance of change in code book |
| 2017-07-01 | Changed | Revise description to include the new FDA approved two-dose schedule for this vaccine and the complete scientific ACIP acronym. |
| 2017-01-01 | Changed | Code description changed. |
| 2016-01-01 | Added | First appearance in codebook. |
| 2015-02-01 | Added | FDA approval received 2014-10-29. Implementation is 2015-02-01. Payers may decide to implement code prior to 2015-02-01. |
Get instant expert-level medical coding assistance.